Oncology Devices Market: Market Size & Forecast 2026

The oncology devices market includes the full range of medical equipment and hardware used to diagnose, stage, treat, and monitor cancer patients, spanning diagnostic imaging systems, radiotherapy delivery platforms, surgical instruments, ablation devices, and infusion systems. With a 2026 valuation of approximately $283.77 billion and an 11.95% compound annual growth rate, the market reflects strong sustained demand across both developed and emerging healthcare systems. This growth aligns with broader oncology sector expansion, where global cancer cases, already at 20 million new diagnoses annually per WHO data, are projected to rise significantly through 2045.

• •Market valued at approximately $283.77 billion in 2026, up from the prior year, expanding at an 11.95% CAGR
• •Covers the full continuum of cancer care: diagnostics, treatment delivery, surgical support, and patient monitoring devices
• •Global cancer incidence at 20 million new cases in 2022, projected to reach 32.6 million by 2045 per WHO data

Rising global cancer incidence is the primary engine of demand, with WHO data showing 20 million new cancer cases worldwide in 2022 and projections reaching 32.6 million by 2045 as populations age and diagnostic access improves across more regions. Advancements in precision oncology, including targeted diagnostic platforms and personalized treatment delivery systems, are driving replacement cycles and new product adoption across healthcare facilities worldwide. Expanding screening programs in emerging markets, combined with growing insurance coverage for advanced oncology procedures, are broadening the addressable patient population for device manufacturers.

• •Aging global populations and rising cancer prevalence creating sustained, long-term demand across all device categories
• •Precision oncology advancements, including molecular diagnostics and targeted therapy platforms, driving new product development cycles
• •Expanding screening infrastructure and insurance coverage in emerging markets broadening the addressable patient base

The market is segmented across diagnostic devices, including imaging systems, biopsy instruments, and molecular diagnostic platforms, and treatment devices such as radiotherapy systems, surgical platforms, ablation equipment, and drug delivery systems, with further divisions by cancer indication including lung, breast, colorectal, prostate, and other types. North America represents the largest regional market, supported by advanced healthcare infrastructure, high per-capita healthcare spending, and early adoption of innovative oncology technologies. Asia-Pacific and emerging markets are growing at an accelerated pace as healthcare systems expand access to cancer screening and treatment, while Europe maintains a significant share through established regulatory pathways and widespread reimbursement frameworks.

• •Key segments include diagnostics (imaging, molecular testing) and therapeutics devices (radiotherapy, surgical, drug delivery systems)
• •North America leads as the largest regional market, supported by advanced infrastructure and early technology adoption
• •Asia-Pacific emerging as the fastest-growing region as healthcare access and cancer screening programs expand

Who are the notable companies in the industry?

The oncology devices industry exhibits a semi-consolidated competitive structure, with a mix of large diversified medical technology firms and specialized producers focused on oncology-specific applications. The sector includes vertically integrated manufacturers that control design, manufacturing, and global distribution networks alongside specialty producers focused on niche therapeutic areas or device categories such as radiation therapy or surgical robotics. Technology and manufacturing routes span conventional radiation delivery systems, robotic-assisted platforms, advanced imaging modalities, and emerging connected health integrations, with production and R&D capacity concentrated in North America, Western Europe, and increasingly in East Asia.

• •Semi-consolidated structure with diversified medical technology firms alongside oncology-focused specialty producers
• •Manufacturing and technology routes include radiotherapy systems, surgical robotics, advanced imaging, and connected health integrations
• •Production capacity and R&D concentrated in North America, Western Europe, and East Asia

What are the recent trends and outlook?

The integration of digital health technologies, including remote patient monitoring, telehealth platforms, and AI-assisted diagnostics, is reshaping how oncology devices are deployed and managed across care settings, enabling more data-driven treatment decisions. Minimally invasive and image-guided treatment approaches continue to displace traditional surgical methods, driving demand for advanced imaging, robotic platforms, and navigation systems. Over the forecast horizon, the market is expected to sustain its 11.95% CAGR as manufacturers invest in connected device ecosystems, AI-enabled platforms, and as emerging markets expand oncology care infrastructure to address growing disease burden.

• •Digital health integration, including AI diagnostics and remote monitoring, becoming a core competitive differentiator
• •Minimally invasive and image-guided treatment platforms gaining share over conventional surgical and radiotherapy methods
• •Market projected to sustain an 11.95% CAGR as emerging market infrastructure investment accelerates